FDA Warns of Unapproved Skincare and Hair Growth Treatments

The U.S. Food and Drug Administration (FDA) has issued warning letters to companies for marketing skincare and hair growth treatments containing unapproved additives, citing potential safety risks and unverified claims. The agency is cautioning consumers about trendy ingredients, such as exosomes, which have gained popularity but lack FDA approval and robust scientific backing.

Exosomes, tiny bubbles derived from human stem cells, are promoted for their ability to expedite cell turnover, improve skin elasticity, reduce hyperpigmentation, and address thinning hairlines. Despite endorsements from celebrities and their growing presence in the aesthetic market, these products have not undergone the rigorous testing and approval processes required by the FDA.

In August 2026, the FDA sent warning letters to clinics like R3 Medical Companies for alleged false product claims and manufacturing failures. This action follows a 2019 public safety notification from the FDA regarding unapproved exosome treatments.

Dr. Gina Maccarone, a cosmetic surgeon, highlighted the risks associated with uncharacterized products. "The honest problem is that when a product is poorly characterized, you can’t fully predict its side effects because you don’t reliably know what’s in it," she told USA Today. While topical applications might carry fewer risks, injected treatments can lead to common reactions like redness or irritation at the injection site, as well as potential allergic reactions.

The lack of comprehensive, long-term scientific data raises concerns about the safety of these treatments over time. The FDA's stance emphasizes the importance of transparency regarding the source of cells, manufacturing quality, and administration by a qualified physician. Products included in registered clinical trials are considered a stronger indicator of safety.

While regulatory hurdles remain, the underlying science behind exosome-based treatments shows promise for various applications, including regenerative medicine for conditions such as Alzheimer's, osteoarthritis, and spinal cord injuries. The market has also seen the emergence of lab-synthesized and plant-derived alternatives, though their functions may differ from human-derived exosomes.